EV is an antibody drug conjugate that consists of an anti-nectin-4-antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. It has proven superior efficacy (overall survival (OS), progression free survival (PFS) and overall response rate (ORR)) in platinum- and immunotherapy refractory bladder cancer and is currently investigated in combination strategies and early treatment lines in UC [24]. The gene discussed is NECTIN4; the disease is urinary bladder carcinoma.